Tagged Articles

SJS 123 articles

Drug reactions bring awareness to Stevens Johnson Syndrome

New reports from the Food and Drug Administration (FDA) and cancer patients have put Revlimid, an oral medicine given to patients with multiple myeloma, on a list of medications that could possibly cause Stevens Johnson Syndrome when used by itself or mixed with other drugs. Stevens Johnson syndrome is a serious, potentially life-threatening skin disease that can start with flu-like symptoms and eventually cause a rash that spreads and blisters. According to mediafact.com, other medications have been linked to Stevens Johnson syndrome including Bextra, Celebrex and Daypro, as well as over-the-counter pain relievers such as Motion, Ibuprofen, Children’s Motrin and ... Read More

FDA finds link between Revlimid and skin diseases

The FDA’s post-market safety review has uncovered a link between lenalidomide (marketed as the drug Revlimid) and serious skin reactions, including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The FDA approved Celgene Corp.’s Revlimid in December 2005 to treat a bone marrow disorder. It was later approved for use in treatment of multiple myeloma, a type of blood cancer. Earlier this month, Revlimid appeared on a list of approximately twenty drugs under investigation by the FDA for possible safety hazards. No details about the specific concerns were made available at that time. From the drug’s approved use in ... Read More

Drug industry seeks tests to spot side effect risks

Seven major pharmaceutical companies are banding together to develop genetic tests that predict which patients will have adverse side effects from drugs. The group, a nonprofit organization dubbed the International Serious Adverse Events Consortium (SAEC), will conduct two studies, one to look at drug-related liver toxicity and the other aimed at a rare drug-related skin condition called Stevens-Johnson syndrome. “SAEC’s focus is to identify and to validate DNA variance or genetic markers that are useful in predicting a drug-induced serious adverse event,” Arthur Holden, the chairman of the group, said during a midmorning teleconference Thursday. The findings of the consortium ... Read More